Skip to main content
Erschienen in: Indian Journal of Gastroenterology 6/2012

01.12.2012 | Short Report

Esophageal adenocarcinoma versus squamous cell carcinoma: retrospective hospital-based analysis of a 12-year temporal trend

verfasst von: Rohan Bhome, Devendra Desai, Philip Abraham, Anand Joshi, Tarun Gupta, Anita Bhaduri, Asha Kapadia, Krishna Patel, Rahul Bhome

Erschienen in: Indian Journal of Gastroenterology | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

There is a paucity of literature from the Indian subcontinent looking at the prevalence of esophageal cancer by histological type. In our study, we ascertained the relative proportion and location of adenocarcinoma (AC) and squamous cell carcinoma (SCC) of the esophagus at a referral hospital in Mumbai, India over a 12-year period to assess whether a time-trend existed. A retrospective analysis was carried out on patients who were diagnosed with and/or treated for esophageal cancer at the P D Hinduja Hospital and Research Centre in Mumbai between January 1, 2000 and December 31, 2011. Data were procured from histopathology and oncology registers of the institute, the database of the Gastroenterology consultants, the Endoscopy Department records and from the Medical Records Department. Of the 445 cases of esophageal cancer with known histology, 104 (23 %) were AC and 314 (71 %) were SCC. Over the 12-year period, the proportions of AC compared to SCC did not show a statistically significant temporal change (p = 0.145). AC comprised nearly a quarter of esophageal carcinoma in Mumbai. There has been no significant change in the number and proportion of AC and SCC in the 12-year period.
Literatur
1.
Zurück zum Zitat Kollarova H, Machova L, Horakova D, Janoutova G, Janout V. Epidemiology of esophageal cancer—an overview article. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007;151:17–20.PubMedCrossRef Kollarova H, Machova L, Horakova D, Janoutova G, Janout V. Epidemiology of esophageal cancer—an overview article. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007;151:17–20.PubMedCrossRef
2.
Zurück zum Zitat Gajalakshmi V, Shanta V, Swaminathan R. Cancer Registration in India. Asian Pacific J Cancer Prev. 2000;2:13–20. Gajalakshmi V, Shanta V, Swaminathan R. Cancer Registration in India. Asian Pacific J Cancer Prev. 2000;2:13–20.
3.
Zurück zum Zitat Mehrotra ML, Lal H, Pant GC, Vaidya MP, Gupta IM. Esophageal carcinoma in India. Some epidemiologic and morphologic considerations. Trop Geogr Med. 1977;29:353–8.PubMed Mehrotra ML, Lal H, Pant GC, Vaidya MP, Gupta IM. Esophageal carcinoma in India. Some epidemiologic and morphologic considerations. Trop Geogr Med. 1977;29:353–8.PubMed
4.
Zurück zum Zitat Gholipour C, Shalchi RA, Abbasi M. A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003. Dis Esophagus. 2008;21:322–7.PubMedCrossRef Gholipour C, Shalchi RA, Abbasi M. A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003. Dis Esophagus. 2008;21:322–7.PubMedCrossRef
5.
Zurück zum Zitat Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1995. Int J Cancer. 2002;99:860–8.PubMedCrossRef Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1995. Int J Cancer. 2002;99:860–8.PubMedCrossRef
6.
Zurück zum Zitat Tony J, Kumar SK, Thomas V. Time trends and pathological profile of carcinoma lower oesophagus and gastro-esophageal junction over the last 20 years—an experience from South India. Trop Gastroenterol. 2007;28:113–6.PubMed Tony J, Kumar SK, Thomas V. Time trends and pathological profile of carcinoma lower oesophagus and gastro-esophageal junction over the last 20 years—an experience from South India. Trop Gastroenterol. 2007;28:113–6.PubMed
7.
Zurück zum Zitat Joshi SC, Saxena SR, Satyawali VN, et al. Esophageal carcinoma—a study of risk factors (emphasis on nutrition) in a teaching hospital of Kumaon region of Uttarakhand. J Assoc Physicians India. 2009;57:631–5.PubMed Joshi SC, Saxena SR, Satyawali VN, et al. Esophageal carcinoma—a study of risk factors (emphasis on nutrition) in a teaching hospital of Kumaon region of Uttarakhand. J Assoc Physicians India. 2009;57:631–5.PubMed
8.
Zurück zum Zitat Cherian JV, Sivaraman R, Muthusamy AK, Jayanthi V. Carcinoma of the esophagus in Tamil Nadu (South India): 16-year trends from a tertiary center. J Gastrointestin Liver Dis. 2007;16:245–9.PubMed Cherian JV, Sivaraman R, Muthusamy AK, Jayanthi V. Carcinoma of the esophagus in Tamil Nadu (South India): 16-year trends from a tertiary center. J Gastrointestin Liver Dis. 2007;16:245–9.PubMed
9.
Zurück zum Zitat Gupta NM, Jindal R, Prakash O, Gupta R, Bhasin DK. Comparison of the clinical profile and outcome for squamous cell carcinoma and adenocarcinoma of the distal esophagus and cardia in India. Surg Today. 2001;31:400–4.PubMedCrossRef Gupta NM, Jindal R, Prakash O, Gupta R, Bhasin DK. Comparison of the clinical profile and outcome for squamous cell carcinoma and adenocarcinoma of the distal esophagus and cardia in India. Surg Today. 2001;31:400–4.PubMedCrossRef
10.
Zurück zum Zitat Chang SS, Lu CL, Chao JY, et al. Unchanging trend of adenocarcinoma of the esophagus and gastric cardia in Taiwan: a 15-year experience in a single center. Dig Dis Sci. 2002;47:735–40.PubMedCrossRef Chang SS, Lu CL, Chao JY, et al. Unchanging trend of adenocarcinoma of the esophagus and gastric cardia in Taiwan: a 15-year experience in a single center. Dig Dis Sci. 2002;47:735–40.PubMedCrossRef
11.
Zurück zum Zitat Ganesh B, Talole SD, Dikshit R. Tobacco, alcohol and tea drinking as risk factors for esophageal cancer: a case-control study from Mumbai, India. Cancer Epidemiol. 2009;33:431–4.PubMedCrossRef Ganesh B, Talole SD, Dikshit R. Tobacco, alcohol and tea drinking as risk factors for esophageal cancer: a case-control study from Mumbai, India. Cancer Epidemiol. 2009;33:431–4.PubMedCrossRef
12.
Zurück zum Zitat Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut. 2005;54 Suppl 1:i1–5.PubMedCrossRef Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut. 2005;54 Suppl 1:i1–5.PubMedCrossRef
Metadaten
Titel
Esophageal adenocarcinoma versus squamous cell carcinoma: retrospective hospital-based analysis of a 12-year temporal trend
verfasst von
Rohan Bhome
Devendra Desai
Philip Abraham
Anand Joshi
Tarun Gupta
Anita Bhaduri
Asha Kapadia
Krishna Patel
Rahul Bhome
Publikationsdatum
01.12.2012
Verlag
Springer-Verlag
Erschienen in
Indian Journal of Gastroenterology / Ausgabe 6/2012
Print ISSN: 0254-8860
Elektronische ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-012-0250-9

Weitere Artikel der Ausgabe 6/2012

Indian Journal of Gastroenterology 6/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.